Fig. 4: Overall survival and treatment-free survival among patients with CLL disease progression on ibrutinib by pattern of progression.

A It compares overall survival by pattern of progression: lymphocytosis without lymphadenopathy, lymphadenopathy without lymphocytosis, or lymphocytosis and lymphadenopathy. B It compares treatment-free survival between the same groups. Note, the five patients with iwCLL-defined disease progression but without lymphadenopathy or lymphocytosis (i.e., biopsy-proven marrow infiltration causing cytopenias, progressive hepatosplenomegaly) are not included in this analysis.